SCHEMBL3439265

SCHEMBL3439265

CCCCCCCNC(=O)N(C)c1cccc(-c2ccc(C[C@H](NC(=O)c3ccccc3)C(=O)O)cc2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.48
PTPN1 P18031 2/20 0.47
ACE P12821 3/20 0.46
MME P08473 1/20 0.46
CPA1 P15085 1/20 0.46
ACE2 Q9BYF1 1/20 0.46
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA9 Q16790 1/20 0.45
NAAA Q02083 1/20 0.45
ITGB3 P05106 5/20 0.45
ITGAV P06756 4/20 0.45
ITGB1 P05556 1/20 0.44
ITGA4 P13612 1/20 0.44
ITGA2B P08514 1/20 0.43
CTSL P07711 1/20 0.43
CTSB P07858 1/20 0.43
CTSS P25774 1/20 0.43
CTSK P43235 1/20 0.43
GRIA1 P42261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3439266 1.00 L3MBTL1 (0.48) L3MBTL1PTPN1ACEMMECPA1
SCHEMBL3439039 0.88 PTGS2 (0.44) ACEMMECPA1ACE2ITGB3
SCHEMBL3439038 0.88 PTGS2 (0.44) ACEMMECPA1ACE2ITGB3
SCHEMBL3439050 0.88 ITGB3 (0.56) ACEMMECPA1ACE2ITGB3
SCHEMBL3439051 0.88 ITGB3 (0.56) ACEMMECPA1ACE2ITGB3
SCHEMBL3439116 0.87 PTGS2 (0.43) ACEMMECPA1ACE2ITGB3
SCHEMBL3439055 0.87 ITGB3 (0.45) ACEMMECPA1ACE2ITGB3
SCHEMBL3439054 0.87 ITGB3 (0.45) ACEMMECPA1ACE2ITGB3
SCHEMBL3439115 0.87 PTGS2 (0.43) ACEMMECPA1ACE2ITGB3
SCHEMBL3439264 0.86 TLR2 (0.48) ACEMMECPA1ACE2ITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090062340-A1 NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-03-05 US claimed
US-20050256116-A1 Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-11-17 US claimed
US-7807669-B2 Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-10-05 US disclosed
US-20090062340-A1 NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-03-05 US disclosed
US-7452878-B2 Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-11-18 US disclosed
US-20050256116-A1 Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062340-A1 NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF PPARG, PPARA, PPARD L3MBTL1 4361/4885PTPN1 998/4885ACE 2858/4885
US-20050256116-A1 Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof PPARG, PPARA, PPARD L3MBTL1 4361/4885PTPN1 998/4885ACE 2858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.